CALT News and Press, Calliditas Therapeutics AB From 05/18/21

The following slide deck was published by Calliditas Therapeutics AB (publ) in conjunction with their 2021 Q1 earnings call. For further details see: Calliditas Therapeutics AB (publ) 2021 Q1 - Results - Earnings Call Presentation

Calliditas Therapeutics (CALT): Q1 GAAP EPS of -SEK 2.51.Cash amounted to SEK 867.3MPress Release For further details see: Calliditas Therapeutics reports Q1 results

Interim Report Q1, 2021 PR Newswire STOCKHOLM , May 18, 2021 /PRNewswire/ -- Filing of New Drug Application submission to the FDA "Following the positive top line readout of our pivotal Phase 3 trial NefIgArd, which met both the primary and key secondary ...

Calliditas Therapeutics to host conference call to provide Business Update for the first quarter of 2021 PR Newswire STOCKHOLM , May 14, 2021 /PRNewswire/ -- On May 18 th , 2021, Calliditas Therapeutics AB (publ) ("Calliditas") will publish its financia...

Calliditas promotes Andrew Udell to President, North America PR Newswire STOCKHOLM , May 3, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that former Head of North America Commerc...

ADMA Biologics (ADMA) +25% after receiving FDA approval for increased IVIG production scale.Akari Therapeutics (AKTX) +12% on receiving FDA fast track designation for Nomacopan.Sphere 3D Corp. (ANY) +12%.RiceBran Technologies (RIBT) +11%.Boxlight Corporation (BOXL) +11%.Calliditas T...

Under Priority Review, the FDA has accepted Calliditas Therapeutics' (CALT) New Drug Application ((NDA)) for Nefecon, a down regulator of IgA1 for the treatment of IgA nephropathy (IgAN.)The FDA has set a PDUFA goal date of September 15, 2021. The NDA submission is based on positive data from...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, investors! We’ve reached the halfway point of the week and there’s no time to start slacking now. As such, get ready for another busy day of trading with our top pre-market stock movers list! ...

FDA grants priority review for Nefecon, for patients with IgA nephropathy PR Newswire STOCKHOLM , April 28, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the U.S. Food and Drug Ad...

Calliditas Therapeutics AB: Change in financial calendar PR Newswire STOCKHOLM , April 27, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) announces today that the Board has decided that the interim report for the first qu...